STUDY OF HEPATOPROTECTIVE ACTIVITY OF A COMBINED FLAMIN/SILYMARIN MIXTURE FROM HERBAL ORIGIN IN EXPERIMENTAL CIRRHOSIS.
Abstract
The aim of this study is to investigate Flamin/Silymarin as a new herbal combined hepatoprotective drug in experimental liver cirrhosis of white rats. Flamin was obtained from the flowers of the reddish immortelle (Helichrysum rubicundum (C. Koch.)), аnd Silymarin from the seeds of the milk thistle (Silybum marianum) growing in Armenia.
The histomorphological studies showed that in comparison with the two control groups under the influence of Flamin/Silymarin the destructive and dystrophic processes are much reduced in the liver parenchyma. The histostructure is mainly preserved: there are binucleated hepatocytes with nucleoli, the boundaries of the interlobular hepatic tracts are clearly formed. Compared with the group treated with Flamin, in animals treated with Flamin/Silymarin, there was a reduction of karyolysis and pyknosis in hepatocytes. Along with this, in some areas, there were small foci of fatty changes. It is assumed that with long-term therapy, the effectiveness of Flamin/Silymarin may be increased.
Consequently, further in-depth study of the mixture will lead to the identification and introduction of a new herbal hepatoprotective for the prevention and treatment of liver cirrhosis.
References
2. Czinner E., Hagymasi K., Blazovics A., Kery A., Szoke E., Lemberkovics E. In vitro antioxidant properties of Helichrysumarenarium (L.) Moench // JEthnopharmacol. 2000. Vol. 73, Is. 3. P. 437–43. DOI: 10.1016/ S03788741(00)003044.
3. Mao Z, Gan C, Zhu J, Ma N, Wu L, Wang L, Wang X. Antiatherosclerotic activities of flavonoids from the flowers of Helichrysum arenarium L. MOENCH through the pathway of antiinflammation // Bioorg Med Chem Lett. – 2017. Vol. 27, No.12. – P. 28122817. DOI: 10.1016/j.bmcl.2017.04.076.
4. Goudzenko A.B., Tsourkan A.A. Elaboration of Approaches to The Standartiz Ofation Helichrysum Arenarium (1.) Moench in Plant Mixtures // Pharmacy & Pharmacology. – 2014. – Vol. 2, No.1(2). – P. 2934. DOI: 10.19163/23079266201421(2)2934.
5. Boyko N.N., Pisarev D.I., Zhilyakova E.T., Novikov O.O. Study and Modeling of Solvent Influence On Isosalipurposide Extraction from Helichrysi Arenarii Flowers // Pharmacy & Pharmacology. – 2018. –Vol. 6, No.4. – P. 340350. (In Russ.) DOI: 10.19163/23079266201864340350.
6. Pljevljakusic D., Bigovic D., Jankovic T., Jelacic S. and Savikin K. Sandy Everlasting (Helichrysumarenarium (L.) Moench): Botanical, Chemical and Biological Properties // Front. Plant Sci. 2018. Vol. 9. P. 1123. DOI: 10.3389/fpls.2018.01123.
7. Kramberger, K.; Jenko Praznikar, Z.; Baruca Arbeiter, A.; Petelin, A.; Bandelj, D.; Kenig, S. A Comparative Study of the Antioxidative Effects of Helichrysum italicum and Helichrysum arenarium Infusions // Antioxidants 2021. – Vol. 10. – P. 380. https://doi.org/10.3390/ antiox10030380.
8. Rigano D, Formisano C, Senatore F, Piacente S, Pagano E, Capasso R, Borrelli F, Izzo AA. Intestinal antispasmodic effects of Helichrysum italicum (Roth) Don ssp. italicum and chemical identification of the active ingredients // J Ethnopharmacol. 2013. – Vol. 150, No.3. – P. 901906. DOI: 10.1016/j.jep.2013.09.034.
9. Ananikyan G.S. Sravnitelnyj analiz antiradikalnoj aktivnosti flavonoidnyh komponentov socvetij bessmertnika krasnovatogo, plodov rastoropshi pyatnistoj i maklyury oranzhevoj // Him.zh.Armenii. 2016. T. 69, No 12. St. 143150. http://chemistry.asjoa.am/id/eprint/7727.
10. Mahli, A., Koch, A., Czech, B. et al. Hepatoprotective effect of oral application of a silymarin extract in carbon tetrachlorideinduced hepatotoxicity in rats // Clin Phytosci. – Vol. 1, No.5. 2015. DOI: 10.1186/s408160150006z.
11. Rigano D., Formisano C., Senatore F., Piacente S., Pagano E., Capasso R., Borrelli F., Izzo A.A. Intestinal antispasmodic effects of Helichrysum italicum (Roth) Don ssp. italicum and chemical identification of the active ingredients // Journal of Ethnopharmacology. – Vol. 150, Is. 3. – 2013. – P. 901906. DOI: 10.1016/j.jep.2013.09.034.
12. Crocenzi F.A., Roma M.G. Silymarin as a new hepatoprotective agent in experimental cholestasis: New possibilities for an ancient medication // Curr. Med. Chem. 2006. – Vol. 13. – P. 1055–1074. DOI: 10.2174/092986706776360950
13. Cacciapuoti F, Scognamiglio A, Palumbo R, Forte R, Cacciapuoti F. Silymarin in nonalcoholic fatty liver disease // World J Hepatol. – 2013. – Vol. 5, No.3. – P. 109113. DOI: 10.4254/wjh.v5.i3.109.
14. Valentova K, Purchartova K, Rydlova L, et al. Sulfated Metabolites of Flavonolignans and 2,3Dehydroflavonolignans: Preparation and Properties // Int J Mol Sci. – 2018. – Vol. 19, No.8. – P.2349. DOI:10.3390/ijms19082349.
15. Linda M. McManus, Richard N. Mitchell, editors. Pathobiology of Human Disease // San Diego: Elsevier. – 2014. P. 17701782. DOI: 10.1016/B978012386456 7.042027.
16. Beyoglu D, Idle JR. Metabolomic and Lipidomic Biomarkers for Premalignant Liver Disease Diagnosis and Therapy // Metabolites. 2020. – Vol.10, No.2. – P. 50. DOI:10.3390/metabo10020050
17. Mukhtar S, Xiaoxiong Z, Qamer S, Saad M, Mubarik MS, Mahmoud AH, Mohammed OB. Hepatoprotective activity of silymarin encapsulation against hepatic damage in albino rats // Saudi J Biol Sci. – 2021. – Vol. 28, No.1. – P. 717723. DOI: 10.1016/j.sjbs.2020.10.063.
18. Moore KP, Aithal GP. Guidelines on the management of ascites in cirrhosis // Gut. 2006. Suppl 6. – P. 112. DOI: 10.1136/gut.2006.099580.
19. Thomson MJ, Lok AS, Tapper EB. Optimizing medication management for patients with cirrhosis: Evidencebased strategies and their outcomes // Liver Int. – 2018. – Vol. 38, No.11. – P. 18821890. DOI: 10.1111/liv.13892.
20. Mnacakanyan V.A., Ananikyan G.S., Babahanyan M.A., Oganesyan L.E., Ovsepyan G.Yu., Sargisyan S.A. Sravnitelnoe izuchenie soderzhaniya zhirnogo masla i flavolignanov v semenah rastoropshi pyatnistoj /Silybummarianum (L.) Gaertn. / pochvennogo i gidroponicheskogo proishozhdeniya. Mezhdunarod. zhurn. prikladnyh i fundamentalnyh issledovanij, 2015, No.12, ch.8, s.14451447.
21. Korzhevskij D.E., Gilyarov A.V. Osnovy gistologicheskoj tehniki. SanktPeterburg. SpecLit, 2010. 95 s.
22. Hung GD, Li PC, Lee HS, Chang HM, Chien CT, Lee KL. Green tea extract supplementation ameliorates CCl4induced hepatic oxidative stress, fibrosis, and acutephase protein expression in rat // J Formos Med Assoc. – 2012. – Volo. 111, No.10. – P. 550559. DOI: 10.1016/j.jfma.2011.06.026.
23. Wang T, Zhao LJ, Li P, Jiang H, Lu GC, Zhang WD, Li HL, Yuan BJ. Hepatoprotective effects and mechanisms of dehydrocavidine in rats with carbon tetrachlorideinduced hepatic fibrosis // J Ethnopharmacol. – 2011. – Vol. 38, No.1. – P. 7684. DOI: 10.1016/j.jep.2011.08.039.
24. Arshakyan L.M., Gasparyan H.G.,
Khachikyan M.H. Morfofunctional state of the liver tissue in the presence of experimental chirrhosis and in condition of treatment with flamin drug of herbal origin // FARMA. 2017. – No.14. P. 5256.
25. HernandezGea V,Friedman SL. Pathogenesis of liver fibrosis. Annu Rev Pathol. – 2011. – Vol. 6. – P. 42556. DOI: 10.1146/annurevpathol011110130246.
CC BY-ND
A work licensed in this way allows the following:
1. The freedom to use and perform the work: The licensee must be allowed to make any use, private or public, of the work.
2. The freedom to study the work and apply the information: The licensee must be allowed to examine the work and to use the knowledge gained from the work in any way. The license may not, for example, restrict "reverse engineering."
2. The freedom to redistribute copies: Copies may be sold, swapped or given away for free, in the same form as the original.